Thelansis

  Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company dedicated to developing gene therapies for retinal degenerative diseases, has announced a successful FDA meeting for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP). Based on the positive regulatory feedback received during the meeting, Nanoscope will begin the submission of a Biologics License Application (BLA) in the first quarter of 2025. This marks a significant step forward in the company’s mission to bring effective treatments to patients suffering from RP. Publish Date: 15-10-2024   Source: Nanoscope Therapeutics Inc. Retinitis pigmentosa (RP) is a hereditary degenerative condition of the retina characterized by night blindness and a gradual loss of peripheral vision, eventually leading to complete blindness. The primary malfunction typically occurs in the rod photoreceptors, causing them to deteriorate progressively. Subsequently, cone cells also per...

 Retinitis pigmentosa (RP) is a hereditary degenerative condition of the retina characterized by night blindness and a gradual loss of peripheral vision, eventually leading to complete blindness. The primary malfunction typically occurs in the rod photoreceptors, causing them to deteriorate progressively. Subsequently, cone cells also perish, likely due to oxidative damage and a lack of nourishment. The age at which symptoms first appear varies widely, not only between families but also among forms of RP. However, once symptoms manifest, the rate and manner of progression tend to follow a fairly predictable and stereotypical exponential pattern. Individuals who take vitamin A, E, or a combination of both have shown slower declines in ERG (electroretinogram) amplitudes compared to those who do not accept these supplements. The treatment of retinitis pigmentosa (RP), the FDA has approved Luxturna (voretigene neparvovec). Luxturna is a gene therapy designed to address a specific subgr...

  Retinitis pigmentosa (RP) is an inherited retinal degeneration characterised by nyctalopia and progressive visual field loss, eventually leading to blindness. The primary defect usually lies in the rod photoreceptors, which gradually degenerate. Secondary cone cell death follows, presumably due to oxidative damage and cone starvation. The age of onset of symptoms is the most variable factor. This can vary not only between families but also within subtypes of RP. However, after that, the rate and modality of progression tend to follow a fairly predictable and stereotyped exponential pattern. There is no curative therapy for retinitis pigmentosa. However, patients who happen to be taking vitamin A, vitamin E, or both were recorded to have slower declines in ERG amplitudes than those not taking such supplements. RP affects about 25 to 30 cases per 100,000 population globally. In the United States, about 128,500 people were diagnosed with RP in 2019, reaching up to 156,...